Eli Lilly & Co. reported the first detailed results from a cardiovascular outcomes trial for the GLP-1 receptor agonist Trulicity (dulaglutide) at the American Diabetes Association's annual meeting on 9 June in San Francisco, showing treatment with Trulicity resulted in a significant 12% reduction in major cardiovascular events in a uniquely broad patient population. But the results were more modest than some investors had expected.
Trulicity competes in a crowded class, so it's unclear if the data will give Trulicity a substantial commercial boost as it works to maintain its market-leading position against competition from Novo Nordisk AS's Ozempic (semaglutide), which
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?